CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
巴西血液学、血液疗法与细胞治疗协会关于基因修饰细胞的共识。II：CD19+ 急性淋巴细胞白血病患者的 CAR-T 细胞治疗
英文原题：Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia.
查看英文原题
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞疗法是急性淋巴细胞白血病（ALL）的一种新型治疗方式，在难治或复发患者中取得了显著疗效。与此同时，CAR-T 治疗也与独特且可能致命的毒性相关，例如细胞因子释放综合征（CRS）和神经系统毒性（ICANS）。本文旨在汇集血液肿瘤学和细胞治疗领域专家的共识，就当前ALL患者使用CAR-T 细胞的情形提出建议。
展开英文摘要原文
Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS).
This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.
论文信息
- 作者
- Seber A、de CastroJunior CG、Kerbauy LN、Hirayama AV、Bonfim C、Fernandes JF、Souza M、Schafell R
- 第一作者单位
- Hospital Samaritano Higienópolis, São Paulo, SP, Brazil; Hospital Infantil Sabará, São Paulo, SP, Brazil.Brazil
- 通讯作者单位
- Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil. Electronic address: rlgc@usp.br.Brazil
- 期刊
- Hematology, transfusion and cell therapy2021 Nov
- 原文标识
- PubMed 34794791 · DOI 10.1016/j.htct.2021.09.002
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →